Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-25T11:58:57.719Z Has data issue: false hasContentIssue false
  • English
  • Français

An approach to treatment resistance in schizophrenia

Published online by Cambridge University Press:  06 August 2018

Stephen R. Marder
Stephen R. Marder*
Affiliation:
West Los Angeles VA Medical Center, Los Angeles, CA 90073, USA
Get access Rights & Permissions [Opens in a new window]

Abstract

Currently, patients with schizophrenia are usually considered refractory to treatment if they continue to be floridly symptomatic despite receiving treatment with conventional antipsychotic agents. Attempts to improve their response by increasing the dosage, adding supplementary drugs, or switching to agents of another class have not been very successful, and may increase side-effects. Clozapine can be effective, but it is a difficult drug to administer and has therefore been reserved for patients who are doing poorly. With the recent introduction of newer, safer antipsychotic agents, however, even patients who have milder refractory symptoms that persist after treatment with conventional antipsychotics can now be treated.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 174 , Issue S37: Focus on schizophrenia , February 1999 , pp. 19 - 22
Copyright
Copyright © The Royal College of Psychiatrists, 1999 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Ames, D., Wirshing, W. C., Marshall, B. D., et al (1997) Risperidone versus haloperidol in treatment resistant schizophrenia. Schizophrenia Research, 24, 193.Google Scholar
Beasley, C. M., Tollefson, G., Tran, P., et al (1996) Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology, 14, 111–123.Google Scholar
Bondolfi, G., Dufour, H., Patris, M., et al (1998) Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. American Journal of Psychiatry, 155, 499–504.Google Scholar
Essock, S. M., Hargreaves, W. A., Covell, N. H., et al (1996) Clozapine's effectiveness for patients in state hospitals: results from a randomized trial. Psychopharmacology Bulletin, 32, 683–697.Google Scholar
Goldberg, T. E., Greenberg, R. D., Griffin, S. J., et al (1993) The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. British Journal of Psychiatry, 162, 43–48.Google Scholar
Green, M. F. (1997) What are the functional consequences of neurocognitive deficits in schizophrenia? American Journal of Psychiatry, 153, 321–330.Google Scholar
Green, M. F., Marshall, B. D. Jr, Wirshing, W. C., et al (1997) Does risperidone improve verbal working memory in treatment-resistant schizophrenia? American Journal of Psychiatry, 154, 799–804.Google ScholarPubMed
Hagger, C., Buckley, P., Kenny, J. T., et al (1993) Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biological Psychiatry 34, 702–712.Google Scholar
Kane, J. M., Honigfeld, G., Singer, J., et al (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison versus chlorpromazine/ benztropine. Archives of General Psychiatry, 45, 789–796.CrossRefGoogle Scholar
Kay, S. R., Opler, L. A. & Lindenmayer, J. P. (1988) Reliability and validity of the Positive and Negative Syndrome Scale for schizophrenics. Psychiatry Research, 23, 99–110.Google Scholar
Kinon, B. J., Kane, J. M., Johns, C., et al (1993) Treatment of neuroleptic resistant schizophrenic relapse. Psychopharmacology Bulletin, 29, 309–314.Google Scholar
Kolakowska, T., Williams, A. O., Ardern, M., et al (1985) Schizophrenia with good and poor outcome. I: Early clinical features, response to neuroleptics and signs of organic dysfunction. British Journal of Psychiatry, 146, 229–239.Google Scholar
Marder, S. R. & Meibach, R. C. (1994) Risperidone in the treatment of schizophrenia. American Journal of Psychiatry, 151, 825–835.Google Scholar
Marder, S. R., Wirshing, W. C. & Ames, D. (1997) New antipsychotic drugs. In Annual of Drug Therapy (eds Dunner, D. L. & Rosenbaum, J. F.), pp. 195–207. Philadelphia, PA: WB Saunders.Google Scholar
National Institute of Mental Health -Psychopharmacology Service Center Collaborative Study Group (1964) Phenothiazine treatment in acute schizophrenia. Archives of General Psychiatry, 10, 246.Google Scholar
Overall, J. E. & Gorham, D. R. (1962) The Brief Psychiatric Rating Scale. Psycological Reports, 10, 799–812.Google Scholar
Pickar, D., Owen, R. R., Lutman, R. E., et al (1992) Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine. Archives of General Psychiatry, 49, 345–353.Google Scholar
Schooler, N. R., Kane, J. M., Marder, S. R., et al (1995) Efficacy of clozapine vs haloperidol in the long term clinical trial: preliminary findings. Schizophrenia Research, 15, 165.Google Scholar
Thompson, C. (1994) The use of high-dose antipsychotic medication. British Journal of Psychiatry, 164, 448–458.CrossRefGoogle ScholarPubMed
Tollefson, G. D., Beasley, C. M. Jr, Tran, P. V., et al (1997) Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective disorders: results of an international collaborative trial. American Journal of Psychiatry, 154, 457–465.Google Scholar
Zimbroff, D. L., Kane, J. M., Tamminga, C. A., et al (1997) Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. American Journal of Psychiatry, 154, 782–791.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.